Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.код для вставкиСкачать
ARTHRITIS & RHEUMATISM Vol. 56, No. 11, November 2007, pp 3793–3804 DOI 10.1002/art.22981 © 2007, American College of Rheumatology Gene Expression Profiling of Peripheral Blood From Patients With Untreated New-Onset Systemic Juvenile Idiopathic Arthritis Reveals Molecular Heterogeneity That May Predict Macrophage Activation Syndrome Ndate Fall,1 Michael Barnes,1 Sherry Thornton,1 Lorie Luyrink,1 Judyann Olson,2 Norman T. Ilowite,3 Beth S. Gottlieb,4 Thomas Griffin,1 David D. Sherry,5 Susan Thompson,1 David N. Glass,1 Robert A. Colbert,1 and Alexei A. Grom1 expressed genes (P < 0.05) that distinguished patients with systemic JIA from healthy controls (n ⴝ 30) were identified. Clustering analysis indicated that expression patterns correlated with serum ferritin levels. Three main clusters distinguished systemic JIA patients with highly elevated ferritin levels (including those with subclinical macrophage activation syndrome) from those with normal or only moderately elevated ferritin levels. The first cluster comprised genes involved in the synthesis of hemoglobins and structural proteins of erythrocytes. This transcriptional profile was consistent with immature nucleated red blood cells, likely reflective of high red blood cell turnover. Also included were transcripts indicating immature granulocytes. The second cluster was enriched for genes involved in cell cycle regulation. The third cluster was enriched for genes involved in innate immune responses, including those involved in the negative regulation of Toll-like receptor/ interleukin-1 receptor–triggered inflammatory cascades and markers of the alternative pathway of macrophage differentiation. Additional differentially expressed genes of interest were those involved in the cytolytic pathway, including SH2D1A and Rab27a. Conclusion. These data indicate that gene expression profiling can be a useful tool for identifying early macrophage activation syndrome in patients with systemic JIA. Objective. Systemic juvenile idiopathic arthritis (JIA) is frequently associated with the development of macrophage activation syndrome. This study was undertaken to better understand the relationship between systemic JIA and macrophage activation syndrome. Methods. Gene expression profiles were examined in 17 patients with untreated new-onset systemic JIA, 5 of whom showed evidence of subclinical macrophage activation syndrome (of whom 2 eventually developed overt macrophage activation syndrome). Peripheral blood mononuclear cells (PBMCs) were separated on Ficoll gradients, and purified RNA was analyzed using Affymetrix GeneChip expression arrays. A fraction of the PBMCs were used for flow cytometry to define the cellular composition of the samples. Results. Two hundred twenty-five differentially Supported in part by NIH grant P01-AR-048929 and by a Translational Research Initiative Grant from the Children’s Hospital Research Foundation of Cincinnati. 1 Ndate Fall, MS, Michael Barnes, PhD, Sherry Thornton, PhD, Lorie Luyrink, BA, Thomas Griffin, MD, PhD, Susan Thompson, PhD, David N. Glass, MD, Robert A. Colbert, MD, PhD, Alexei A. Grom, MD: Children’s Hospital Medical Center, Cincinnati, Ohio; 2 Judyann Olson, MD: Medical College of Wisconsin, Milwaukee; 3 Norman T. Ilowite, MD: Albert Einstein College of Medicine, Bronx, New York; 4Beth S. Gottlieb, MD, MS: Schneider Children’s Hospital, New Hyde Park, New York; 5David D. Sherry, MD: Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. Dr. Ilowite has received consulting fees, speaking fees, and/or honoraria (less than $10,000 each) from Amgen and Xoma. Address correspondence and reprint requests to Alexei A. Grom, MD, Children’s Hospital Medical Center, Division of Rheumatology, Pavilion Building, 2-129, 3333 Burnet Avenue, Cincinnati, OH 45229. E-mail: email@example.com. Submitted for publication May 7, 2007; accepted in revised form July 20, 2007. At onset, systemic juvenile idiopathic arthritis (JIA), which constitutes ⬃10% of all cases of JIA, is distinguished from other forms of JIA by the prominence of extraarticular features, such as spiking fevers, 3793 3794 typical fleeting pink macular rash, generalized lymphadenopathy, hepatosplenomegaly, and occasionally, polyserositis (1). The typical laboratory features include marked polymorphonuclear leukocytosis and thrombocytosis. The clinical course during the later stages of systemic JIA is highly variable (1). The systemic features tend to subside during the initial months to years of the disease. Approximately half of children with systemic JIA recover almost completely. The other half continue to have progressive involvement of more joints. The joint disease seen in systemic JIA is in some respects quite different from that in the other JIA subtypes. The distinctive features include early destructive changes in the joints and ankylosis involving the cervical spine, wrists, and midfoot (2). The pathogenetic mechanisms underlying the heterogeneity of systemic JIA are not well understood. Several lines of evidence suggest that the role of the adaptive immune response in systemic JIA may be rather limited compared with its role in other clinical forms of the disease. In contrast, the contribution of innate immunity may be much more prominent (3). On this basis, many view systemic JIA as an autoinflammatory disorder. The relatively good clinical response of systemic JIA to inhibition of interleukin-6 (IL-6) (4,5) and/or IL-1 (6–8), therapeutic interventions that are effective in autoinflammatory diseases with a known genetic cause (9,10), is certainly consistent with this view. A perplexing feature of systemic JIA is its association with macrophage activation syndrome. Macrophage activation syndrome is a severe, potentially lifethreatening complication characterized by the excessive activation of well-differentiated macrophages, resulting in fever, hepatosplenomegaly, lymphadenopathy, severe cytopenias, liver disease, and intravascular coagulation (11). Most notably, the activated macrophages in this syndrome exhibit hemophagocytic activity: they phagocytose normal hematopoietic elements, a phenomenon that leads to the development of life-threatening cytopenias. Macrophage activation syndrome is seen usually in association with systemic JIA, and very rarely with other rheumatic diseases. It accounts for much of the significant morbidity and mortality associated with systemic JIA. At least 10% of patients with systemic JIA develop macrophage activation syndrome at some time during the course of the disease (12). Two recent studies demonstrated the existence of “subclinical macrophage activation syndrome” in approximately one-third of patients with new-onset systemic JIA (13,14). FALL ET AL It is now increasingly recognized that macrophage activation syndrome bears close resemblance to a group of histiocytic disorders collectively known as hemophagocytic lymphohistiocytosis (15,16). Hemophagocytic lymphohistiocytosis can be primary (familial) or secondary (associated with infection or malignancy) (17). One of the early events in hemophagocytic lymphohistiocytosis/macrophage activation syndrome is an uncontrolled and persistent expansion of activated T lymphocytes and hemophagocytic macrophages. These macrophages express CD163 (13,14,18), a scavenger receptor that recognizes hemoglobin–haptoglobin complexes (19). CD163 appears to be expressed mainly on alternatively activated phagocytic macrophages performing “scavenger” functions (20,21). Increased uptake of hemoglobin–haptoglobin complexes by macrophages leads to increased synthesis of ferritin, an acute-phase response protein that binds free iron to prevent oxidative damage (18). A highly elevated level of serum ferritin is an important diagnostic feature of hemophagocytic syndromes (16,17). The most consistent underlying immunologic defect reported in patients with hemophagocytic lymphohistiocytosis has been impairment of cytotoxic functions (16,17). In ⬃40% of patients with primary hemophagocytic lymphohistiocytosis, these immunologic abnormalities have been linked to mutations in the gene encoding perforin, a protein that mediates cytotoxic activity of natural killer (NK) and T cells (22). Other mutations recently implicated in primary hemophagocytic lymphohistiocytosis affect some other proteins involved in the cytolytic pathway (23). Of note, similar immunologic abnormalities, i.e., poor NK cell cytolytic activity, often associated with abnormal levels of perforin expression, have also been reported to distinguish systemic JIA from other forms of childhood arthritis (24). Identification of the immunologic pathways leading to the increased incidence of macrophage activation syndrome in systemic JIA may help not only with early diagnosis of macrophage activation syndrome, but also with identification of children at risk for macrophage activation syndrome at the time of systemic JIA diagnosis, when different management strategies might avert the development of the syndrome. The microarray technology that allows simultaneous assessment of the expression of thousands of genes has provided a new approach to better understand pathogenesis and to define the molecular basis for clinical heterogeneity of many diseases, including JIA (25) and systemic lupus erythematosus (26). We hypothesized that patients with systemic JIA who have early-stage macrophage activa- GENE EXPRESSION PROFILING FOR MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JIA 3795 Table 1. Clinical characteristics of the patients with new-onset systemic juvenile idiopathic arthritis* Patient Characteristic 1† 2 3 4 5† Age, years 15 4.5 14 4.5 4 Sex M F F M M Disease duration, weeks 12 6 11 3 5 Fever ⫹ ⫹ ⫹ ⫹ ⫹ Rash ⫹ ⫹ ⫹ ⫺ ⫹ Arthritis ⫹ ⫹ ⫹ ⫹ ⫹ Hepatosplenomegaly ⫺ ⫹ ⫺ ⫺ ⫺ Lymphadenopathy ⫹ ⫹ ⫺ ⫺ ⫺ Serositis ⫺ ⫹ ⫺ ⫺ ⫺ 9.4 28.9 8.6 19.9 23.2 WBCs, ⫻103/l Hemoglobin, gm/dl 10.8 8.1 7.5 7.6 9.7 Platelets, ⫻103/l 304 344 400 364 718 ESR, mm/hour 108 61 79 140 77 CRP, mg/dl 5.2 20.1 16.3 18.9 4.9 Serum ALT, units/liter NA 16 8 9 29 Serum AST, units/liter NA 60 43 36 21 D-dimers, g/ml NA 2.4 2.1 NA NA Serum ferritin, ng/ml 3,471 6,228 2,950 1,541 2,470 6 13 F ⬎2 ⫹ ⫹ ⫹ ⫺ ⫹ ⫺ 14.4 11.2 453 44 NA NA NA NA 48 7 8 9 10 11 12 13 14 15 16 17 11 2 3 3 14 6 1.5 2 5 3.5 3 F M M F M M F M F F M 5 12 1 8 16 8 ⬎12 6 9 ⬎12 6 ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫹ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫹ ⫹ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫹ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ ⫺ 23.4 18.4 25.5 25.1 27.4 5.4 14.3 13.5 18.5 8.3 20.6 9 8.8 13 9.9 11.2 9.1 10.8 9.2 9.4 10.6 10.5 693 522 835 603 521 670 505 504 677 519 427 140 59 51 98 115 ⬎140 63 NA 109 34 74 23 11.8 2.8 14.4 NA NA 2.2 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 938 1,896 1,247 1,124 1,300 84 63 137 1,339 39 209 * WBCs ⫽ white blood cells; ESR ⫽ erythrocyte sedimentation rate; NA ⫽ not available; CRP ⫽ C-reactive protein; ALT ⫽ alanine aminotransferase; AST ⫽ aspartate aminotransferase. † Patient later developed macrophage activation syndrome. tion syndrome could be identified based on their gene expression profiles in peripheral blood, and the present study was conducted to investigate this. PATIENTS AND METHODS Patients. After written informed consent was provided by their legal guardians, the patients described herein were enrolled in an institutional review board–approved prospective multicenter study of gene expression profiles in childhood arthritis. Systemic JIA was diagnosed based on the International League of Associations for Rheumatology diagnostic criteria (27). The clinical phenotypes of the majority of the patients with systemic JIA have been described previously (13). Nine of the 17 patients with new-onset JIA were male and 8 were female; the median age was 4.5 years. The duration of disease at the time of enrollment ranged from 1 week to 16 weeks (Table 1). Peripheral blood samples were obtained during routine clinic visits prior to the initiation of treatment with disease modifying antirheumatic drugs or steroids. As previously described (13), 5 patients (patients 1–5 in Table 1) had suspected subclinical macrophage activation syndrome based on mild relative cytopenias, hyperferritinemia, and increased serum levels of 2 potential macrophage activation syndrome biomarkers, soluble CD163 (sCD163) and soluble IL-2 receptor (sIL-2R) ␣-chains (13). Two of these 5 patients eventually developed overt macrophage activation syndrome. The control group consisted of 30 healthy children (11 male and 19 female, median age 11.4 years). Sample collection. Of the 17 patients with systemic JIA, 12 were from Cincinnati Children’s Hospital Medical Center (CCHMC), 2 from Milwaukee, 1 from Children’s Hospital of Philadelphia, and 2 from Schneider Children’s Hospital. Whole blood was collected using sodium heparin as an anticoagulant. In all participating centers, peripheral blood mononuclear cells (PBMCs) were separated by Ficoll gradient centrifugation, placed in TRIzol within 4 hours of blood collection, frozen, and stored at ⫺80°C. Special effort was made to ensure the uniformity of sample collection and processing in all participating centers. Personnel from all participating centers received training at CCHMC, RNA samples were prepared by a single technician at CCHMC, and all control samples were collected at CCHMC. For immunophenotyping of the samples, a fraction of the PBMCs was placed in freezing media and stored at ⫺80°C. A separate serum sample for ferritin assessment was collected and also stored frozen at ⫺80°C. All samples were shipped overnight on dry ice to CCHMC. Microarray analysis. All RNA samples were prepared at the coordinating center (CCHMC) and sent to the CCHMC Affymetrix core for processing. RNA quality was assessed on a Bioanalyzer (Agilent, Wilmington, DE) prior to labeling. For microarray analysis, labeled complementary DNA (cDNA) was synthesized from total RNA using the Ovation Biotin RNA Amplification and Labeling System (NuGen, San Carlos, CA). Labeled cDNA was hybridized to Affymetrix U133plus2.0 GeneChip. Data quality was assessed using the standard metrics of the CCHMC Affymetrix core, which include assessment of positive and negative control features on the arrays. Expression values were derived using the Robust Multiarray Average (RMA) preprocessing method as implemented in GeneSpring GX 7.3 (Agilent). The RMA preprocessing was performed on a large data set that included patients with other diseases. The data discussed in this report have been deposited in NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/ geo/ [accession no. GSE7753]). 3796 FALL ET AL Figure 1. Flow cytometric analysis of peripheral blood mononuclear cells (PBMCs) isolated from patients with untreated new-onset systemic juvenile idiopathic arthritis (n ⫽ 9) (solid bars) and from healthy controls (n ⫽ 30) (stippled bars). Samples were stained for the markers of specific cell types present in PBMCs. A, Natural killer (NK) cells (CD3⫺,CD56⫹), CD56dim NK cells (CD3⫺,CD56⫹dim), CD56bright NK cells (CD3⫺,CD56bright), NKT cells (CD3⫹,CD56⫹), CD4⫹ T cells (CD4⫹,CD3⫹,CD25⫺), CD8⫹ T cells (CD8⫹,CD3⫹), Treg cells (CD4⫹,CD3⫹,CD25⫹), B cells (CD19⫹CD3⫺), and mature myeloid cells (mainly monocytes) (CD45⫹,CD33⫹). B, Immature granulocytes (CD15⫹,CD16⫺), granulocytes (CD15⫹,CD16⫹), and hematopoietic cells (CD34⫹). Values are the mean and SD.夹 ⫽ P ⬍ 0.01; 夹夹 ⫽ P ⬍ 0.05 versus controls, by Student’s t-test. Flow cytometric analysis. Single-cell suspensions of PBMCs from patients with systemic JIA and healthy controls were stained with fluorescein isothiocyanate (FITC)– conjugated anti-CD16, phycoerythrin (PE)–conjugated antiCD15, allophycocyanin (APC)–conjugated anti-CD56, peridin chlorophyll protein (PerCP)–conjugated anti-CD3, FITCconjugated anti-CD8, APC-conjugated anti-CD4, PEconjugated anti-CD25, FITC-conjugated anti-CD34, APCconjugated anti-CD19, PerCP-conjugated anti-CD45, and APC-conjugated anti-CD33 (all from BD Biosciences, San Jose, CA). Cells were gated on forward and side scatter parameters and analyzed on a FACSCalibur flow cytometer (BD Biosciences) using CellQuest software. Each cell population is presented as percentage of the total PBMCs. Statistical analysis. Microarray expression values were analyzed using algorithms available in GeneSpring GX 7.3. RMA preprocessing was used to control for chip-to-chip variation. Each probe set was then normalized to the median expression of that probe set in the control samples. Differential expression values were identified by analysis of variance and/or Student’s t-test. In the Affymetrix U133plus2.0 GeneChip, a number of genes are represented by ⬎1 oligonucleotide probe set. In some analyses, when the list of differentially expressed genes included multiple probe sets representing the same gene, only the probe with the lowest P value was included. Hierarchical clustering using complete linkage was used to group genes and samples by expression patterns. RESULTS PBMC immunophenotyping. When the overall number of isolated PBMCs was sufficient, a fraction of the cells was used for flow cytometry to define the cellular composition of the samples to be used in microarray experiments. As shown in Figure 1A, the GENE EXPRESSION PROFILING FOR MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JIA relative cellular composition of PBMC preparations from patients with systemic JIA (n ⫽ 9) was similar to that of controls (n ⫽ 30), with the exception of a mild decrease in the proportion of NK cells in the group of patients with systemic JIA (P ⬍ 0.05 by Student’s t-test). This difference was even stronger when the population of CD56dim NK cells was analyzed separately (P ⬍ 0.01 by Student’s t-test). There was a trend toward an increased proportion of monocytes in patients with systemic JIA, but the difference from controls did not reach statistical significance. Also worth noting was a small but statistically significant increase in the proportion of immature CD34⫹ hematopoietic cells in PBMC preparations from patients with systemic JIA (P ⬍ 0.05 by Student’s t-test) (Figure 1B). There were no statistically significant differences between patients and controls in the numbers of NK T cells, B lymphocytes, CD4⫹ T lymphocytes, CD8⫹ lymphocytes, or Treg (CD4⫹, CD25⫹) cells. Genes differentially expressed in patients with new-onset systemic JIA compared with healthy controls. Microarray-generated gene expression levels were analyzed as described in Patients and Methods. To identify genes that were differentially expressed between healthy controls and patients with untreated new-onset systemic JIA, a rather stringent statistical approach (P ⬍ 0.05 by t-test, with Bonferroni correction for multiple comparisons) yielded a list of 284 differentially expressed probe sets. Elimination of the redundant probe sets as described in Patients and Methods yielded a list of 225 differentially expressed genes. The expression of 147 genes was increased, and the expression of 78 genes was decreased, in systemic JIA patients compared with healthy controls. The median age of the control group (11.4 years) was higher than that of the systemic JIA patients (4.5 years). To ensure that the age difference did not contribute to the differences in gene expression, a further analysis was performed. The control group was divided into 2 subgroups: those above and those below the median age. Subgroups were compared to determine genes whose expression varied with age. This analysis yielded a list of genes (P ⬍ 0.05 by t-test, with Bonferroni correction) that did not include any of the genes that had been found to be differentially expressed in patients with systemic JIA compared with controls, suggesting that the age difference did not contribute to the observed differences in gene expression between patients and controls. Systemic JIA heterogeneity based on clustering analysis of differentially expressed genes. The 225 differentially expressed genes were analyzed by hierarchi- 3797 cal clustering using the complete linkage clustering algorithm, in which distance between samples is inversely proportional to similarity (Figure 2). The systemic JIA patients clustered together, with the exception of 1 individual. Interestingly, this patient (patient 17 in Table 1) was asymptomatic at the 9-month followup, after treatment with only nonsteroidal antiinflammatory drugs. In contrast, all other patients with new-onset systemic JIA had persistent disease. Although these systemic JIA patients clustered, heterogeneity in gene expression was noted, and was reflected in higher-level “branching” of the clustering tree (Figure 2). At least 5 distinct gene clusters contributed to the heterogeneity of systemic JIA (Figure 2). Two clusters included genes whose expression was lower in systemic JIA patients compared with healthy individuals. Cluster 1 comprised various genes. Cluster 2 was enriched for genes involved in cell physiology, genes encoding NK receptors (including several killer cell lectin- and immunoglobulin-like receptors), and genes involved in the regulation of cell cycle and apoptosis. The genes in the remaining 3 clusters exhibited higher expression in patients with systemic JIA compared with healthy controls. Cluster 3 was enriched for genes implicated in the innate immune response to pathogens, most notably genes involved in negative regulation of such responses (e.g., SOCS3 [the gene for suppressor of cytokine signaling protein 3, or SOCS-3] and ADM [the gene for adrenomedullin]). It also included markers of the monocyte/macrophage pathway of cell differentiation (CD64, MS4A4A [the gene for membrane-spanning 4 domain, subfamily A, member 4], and GPR84 [the gene for orphan G-protein–coupled receptor 84]). Several genes involved in the regulation of coagulation (genes for protein S, hemostatic tissue factor inhibitor, and thrombospondin) were also present in this cluster. Cluster 4 was enriched for genes involved in the regulation of cell cycle, chromatin/nucleosome assembly, regulation of transcription, and apoptosis. Cluster 5 was highly enriched for genes involved in the processes of hemoglobin synthesis and oxygen transport, genes encoding structural proteins of red blood cells (RBCs), as well as genes encoding rare hemoglobins, suggesting that this cluster of genes might represent the signature of the immature nucleated RBCs that can copurify with PBMCs isolated on Ficoll gradients. Clinical phenotypes in relation to clustering. To determine whether clinical phenotypes in these patients with systemic JIA correlated with the gene clusters, we compared the position of individual patients in the clustering tree with their clinical features. All patients 3798 FALL ET AL Figure 2. Clustering analysis of the genes differentially expressed between patients with systemic JIA (SJIA) and controls. The list of differentially expressed genes was generated using Student’s t-test, with Bonferroni-corrected P values less than 0.05 considered significant. Redundant probes were eliminated as described in Patients and Methods. The complete linkage clustering algorithm, in which distance is a measure of similarity, was used to generate the hierarchical clustering tree. In this tree, each row represents a separate gene and each column represents a separate individual. The normalized expression level for each gene (rows) in each sample (columns) is indicated by color. Red, yellow, and blue rectangles reflect expression levels that are greater than, equal to, or less than the mean expression level in healthy controls, respectively. The colored line below the tree indicates patients (blue) versus controls (yellow). The colored boxes above the tree distinguish patients in the normal-ferritin group (blue) versus those in the high-ferritin group (red). Patients with subclinical macrophage activation syndrome (MAS) (as defined previously ) are indicated by stars. Note that 1 patient who initially met the diagnostic criteria for systemic JIA, but recovered from the disease within 9 months after being treated with only nonsteroidal antiinflammatory drugs, clustered with the healthy controls. NK ⫽ natural killer. had arthritis and active systemic disease (i.e., characteristic spiking fevers and rash) at the time of sampling. Laboratory findings were reflective of high inflammatory activity in all patients (Table 1) and did not correlate with patient clustering. The extent of the joint disease was highly variable, ranging from mild oligoarticular to severe polyarticular disease, and failed to correlate with the observed clustering (data not shown). Since one of the major diagnostic criteria of hemophagocytic syndromes is extreme hyperferritinemia, we assessed ferritin levels in the serum samples from systemic JIA patients collected at the same time as the PBMC samples for gene expression profiling. As shown in Table 1, although the levels were highly variable, there were 2 distinct subgroups of patients: those with normal or only slightly elevated levels of ferritin (ⱕ209 ng/ml) and those with very high ferritin levels that were comparable with levels observed in GENE EXPRESSION PROFILING FOR MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JIA 3799 Table 2. Innate immune response gene cluster* Description Common name Probe ID P Fold change† Solute carrier family 25 member 37 Elastase 2, neutrophil Resistin Hypothetical protein MGC17301 Eukaryotic translation initiation factor 2c, 2 Ubiquitin-specific protease 32 Peptidoglycan recognition protein 1 Inhibin ␤A Bactericidal/permeability increasing protein Ribonuclease, RNase A family 3 Secretory leukocyte protease inhibitor Carcinoembryonic antigen–related cell adhesion molecule 6 Myeloperoxidase Carcinoembryonic antigen–related cell adhesion molecule 1 Haptoglobin Haptoglobin-related protein Suppressor of cytokine signaling 3 Adrenomedullin Family with sequence similarity 20, member A Membrane-spanning 4 domain, subfamily A, member 4 MSCP ELA2 RETN MGC17301 EIF2C2 USP32 PGLYRP1 INHBA BPI RNASE3 SLPI CEACAM6 MPO CEACAM1 HP HPR SOCS3 ADM FAM20A MS4A4A 226179_at 206871_at 220570_at 227055_at 225827_at 211702_s_at 207384_at 227140_at 205557_at 206851_at 203021_at 203757_s_at 203949_at 209498_at 206697_s_at 208470_s_at 206359_at 202912_at 241981_at 1555728_a_at 3.41 ⫻ 10⫺8 1.88 ⫻ 10⫺6 1.10 ⫻ 10⫺6 9.92 ⫻ 10⫺5 8.48 ⫻ 10⫺5 3.68 ⫻ 10⫺6 2.33 ⫻ 10⫺7 0.0042 4.82 ⫻ 10⫺5 0.000271 2.82 ⫻ 10⫺5 8.88 ⫻ 10⫺5 3.75 ⫻ 10⫺5 0.000342 4.43 ⫻ 10⫺6 2.02 ⫻ 10⫺6 5.52 ⫻ 10⫺6 5.31 ⫻ 10⫺6 6.26 ⫻ 10⫺9 1.04 ⫻ 10⫺7 1.82 2.81 2.95 2.00 2.00 2.02 2.34 6.49 8.72 5.83 5.08 8.16 4.53 2.68 2.93 2.98 1.26 1.85 2.35 1.71 * Cluster of genes selected from a list of probe sets that passed a one-way analysis of variance with a P value cutoff of 0.01 after Bonferroni correction for multiple testing (conditions: “normal-ferritin,” “high-ferritin,” and control groups). † In the “high-ferritin” versus the “normal-ferritin” group, among patients with new-onset systemic juvenile idiopathic arthritis. hemophagocytic syndromes (ⱖ938 ng/ml). As shown in Figure 2, there was a trend toward separation of these 2 groups of patients in the clustering tree. The 5 patients in whom subclinical macrophage activation syndrome was suspected based on mild relative cytopenias and increased levels of sCD163 and sIL-2R ␣-chains (2 putative macrophage activation syndrome biomarkers ) clustered within the “high-ferritin” group. Since separation based on the degree of hyperferritinemia may reflect important pathogenetic differences, the subsequent analysis included comparison between “normalferritin” and “high-ferritin” groups. The “innate immune response” cluster. Some of the genes comprising the innate immune response cluster are listed in Table 2. The list included the monocyte markers CD64 and MS4A4A. There were several genes whose expression is strongly up-regulated in the innate immune response, including those triggered by Toll-like receptor (TLR)/IL-1R signaling (SOCS3, ADM, BPI [the gene for bactericidal/permeability increasing protein], INHBA [the gene for activin A, or inhibin ␤A], SLPI [the gene for secretory leukoprotease inhibitor], PGLYRP1 [the gene for peptidoglycan recognition protein 1], and RETN [the gene for resistin]). Other genes in the cluster included solute carrier MSCP (the gene for solute carrier family 25 member 37 [also known as mitoferrin]), CEACAM1 (the gene for carcinoembryonic antigen–related cell adhesion molecule 1), and CEACAM6/6. There were 2 neutrophil-derived proteins (ELA2 [the gene for elastase 2] and MPO [the gene for myeloperoxidase]), and FAM20A, a protein that plays a role in myelocytic lineage commitment (28), was included. The cluster also included the genes for haptoglobin and haptoglobin-related protein. In our data set, the levels of expression of 12 of the 16 genes in the cluster were significantly higher in the group of patients with high ferritin levels (Figure 3A). Haptoglobin-correlated genes. The gene encoding haptoglobin was one of the most highly overexpressed genes not only in the innate immune response cluster, but also in the entire data set. Since haptoglobin is associated with the pathogenetic pathways relevant to macrophage activation syndrome, we then investigated for genes with expression patterns closely correlated with the expression of the haptoglobin gene. In addition to the entire previously described innate immune response cluster, the group of haptoglobin-correlated genes included several genes encoding antiinflammatory molecules, such as IL-1R antagonist and the light chain of ferritin. Pearson correlation coefficients for these genes were ⱖ0.7, suggesting that their expression was highly coregulated. Cytolytic pathway in systemic JIA patients with high versus normal ferritin levels. The development of the primary hemophagocytic syndromes has been linked to the abnormal cytolytic function of NK cells, NK T 3800 FALL ET AL pathway. We focused on the genes that are 1) involved in the cytolytic pathway and 2) associated with the primary genetic hemophagocytic syndromes. As shown in Figure 3B, the levels of expression of 2 genes, SH2D1A (Xlinked lymphoproliferative disease) and Rab27a (type 2 Griscelli syndrome) differed significantly between the normal-ferritin and high-ferritin groups of patients with systemic JIA (P ⬍ 0.05 by Student’s t-test). DISCUSSION Figure 3. Differences in gene expression between systemic juvenile idiopathic arthritis patients in the high-ferritin group (solid bars) and those in the normal-ferritin group (stippled bars). Expression levels of each individual gene for each patient were normalized against the mean expression level in controls (i.e., fold change, with the mean expression level in controls set at 1). A, Genes from the innate immune response cluster. B, Genes involved in the cytolytic pathway and associated with genetic hemophagocytic syndromes (PRF1 associated with familial hemophagocytic lymphohistiocytosis [HLH] type 2 , MUNC 13-4 with familial HLH type 3 , STX11 with familial HLH type 4 , Rab27a with type 2 Griscelli syndrome , SH2D1A with X-linked lymphoproliferative disease , and LYST with ChédiakHigashi syndrome ). Values are the mean and SD. 夹 ⫽ P ⬍ 0.01; 夹夹 ⫽ P ⬍ 0.05 versus controls, by Student’s t-test. cells, and cytotoxic CD8⫹ T cells. Thus, we were interested in whether the 2 groups of systemic JIA patients could be distinguished based on levels of expression of the genes whose products are involved in the cytolytic The current study of gene expression profiles in the peripheral blood of patients with untreated newonset systemic JIA revealed a strong signature that distinguished patients from healthy controls. Considering the highly distinct clinical phenotype and the systemic nature of the disease, this was not surprising. The more intriguing finding was the heterogeneity of patients with systemic JIA, correlating with some clinical features of macrophage activation syndrome. Thus, hierarchical clustering analysis of the differentially expressed genes revealed at least 2 subgroups of patients with several clusters of genes contributing to the observed heterogeneity. Overall, the expression patterns correlated with serum levels of ferritin, and patients with subclinical macrophage activation syndrome clustered within the high-ferritin group. Since a very high serum level of ferritin is an important diagnostic feature of hemophagocytic syndromes, this distinction may reflect important differences relevant to the pathogenesis of macrophage activation syndrome. We have termed one group of genes that distinguished high-ferritin versus normal-ferritin systemic JIA an “erythropoiesis” cluster. Based on the genes present in this cluster, it likely represents immature nucleated RBCs that are present in PBMC preparations. Since a fraction of the immature nucleated RBCs are CD34⫹ (29), these cells probably contribute to the small but statistically significant expansion of CD34 cells in patients with systemic JIA compared with healthy controls, as determined by flow cytometric analysis (Figure 1). The increased numbers of these cells in most patients with systemic JIA probably reflect the highly increased turnover of RBCs. The fact that this signature is particularly strong in patients with high ferritin levels suggests that these patients may have increased destruction of RBCs, perhaps due to subclinical hemophagocytosis. Consistent with this notion, subclinical macrophage activation syndrome and mild hemophagocytosis have been demonstrated in approximately one-third of patients with new-onset systemic JIA (13,14). GENE EXPRESSION PROFILING FOR MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JIA The main trends in another interesting cluster, designated the “innate immune response” cluster, included 1) increased expression of genes associated with monocyte/macrophage lineage (CD64, GPR84, and MS4A4A), 2) increased expression of antimicrobial peptides (e.g., BPI, PGLYRP1), whose expression appears to be induced by TLR/IL-1R signaling pathways (30), and 3) increased expression of genes involved in the negative feedback regulation of innate inflammatory response (e.g., SOCS3, ADM, INHBA, SLPI, HP). The presence of MS4A4A in the innate immune response cluster is intriguing. MS4A4A is a member of the family of molecules expressed in hematopoietic cells at different stages of their differentiation (31). Expression of MS4A4A strongly increases in monocytes undergoing differentiation into macrophages, especially those following the alternative pathway of macrophage differentiation (32). GPR84 is another marker whose expression is markedly induced in monocytes differentiating into macrophages (33). In our previous study, we noted highly increased serum levels of sCD163, suggestive of expansion of CD163⫹ macrophages, in a subgroup of patients with systemic JIA (13). Surprisingly, in the current data set the expression of CD163 itself was not significantly higher in patients with systemic JIA compared with controls. This is likely related to the fact that by the time macrophages up-regulate the expression of CD163, they tend to leave the peripheral circulation and accumulate in tissue. The small expansion of monocytes in PBMC preparations from patients with systemic JIA (Figure 1) might have contributed to the increase in the numbers of transcripts of the monocyte/macrophage markers. However, a very high degree of overrepresentation of these transcripts (ⱖ1.7-fold change, compared with only a mild degree of expansion of monocytes) suggests that the observed expression patterns are related to increased gene expression in these cells, rather than solely to the increase in their numbers. The activated status of the myeloid cells in systemic JIA is also evident based on the increased numbers of transcripts whose expression was induced during the innate immune responses triggered by TLR/IL-1R signaling. This includes such genes in the immune cluster as ADM (34,35), BPI (36), INHBA (37,38), PGLYRP1 (30,39), and SLPI (40). These findings are consistent with previous reports implicating IL-1 in the pathogenesis of systemic JIA (6–8). Interestingly, products of many genes in the cluster have been shown to participate in the negative feedback loops involved in the down-regulation of the TLR/IL-1R–mediated inflammation. One example is SOCS-3. It belongs to the 3801 SOCS family of proteins, which are up-regulated during innate immune responses, in which they are key negative regulators of cytokine signaling (41–43). In our data set, the innate immune response cluster was much more prominent in the group of patients with high ferritin levels (Figure 3A). The genes for haptoglobin and haptoglobinrelated protein were other genes in the innate immune response cluster. Since hemoglobin–haptoglobin complexes are recognized by CD163, we identified genes whose expression patterns closely correlated with the expression of the haptoglobin gene. In addition to the entire innate immune response cluster, the list of the haptoglobin-correlated genes included those for IL-1R antagonist and the light chain of ferritin. This observation suggests that high levels of ferritin seen in a subgroup of patients with systemic JIA may be a part of the antiinflammatory cascade described above. This is consistent with current understanding of the role of haptoglobin and ferritin in prevention of oxidative damage induced by iron-derived reactive oxygen species (Figure 4), a phenomenon that likely accompanies increased RBC turnover. Results of the clustering analysis, as well as the analysis of haptoglobin-correlated genes, suggest coregulated expression of the marker of the alternative pathway of macrophage differentiation (MS4A4A) (32), haptoglobin, and several negative regulators of innate immune responses, including SOCS-3. SOCS-3 is induced by a number of proinflammatory cytokines, most notably, IL-1 (41,42) and IL-6 (43). It interferes with the signaling pathways of these cytokines, thus providing a negative feedback loop in inflammatory cascades induced by IL-1/IL-6. SOCS-3 may also alter the responsiveness of monocytes to interferon-␥ (IFN␥) (41) and induce switching from Th1 to Th2 immune responses (44). Coregulated expression of the markers of the alternative pathway of macrophage differentiation and several negative regulators of innate immune responses including SOCS-3 raises the question as to whether in new-onset systemic JIA, the induced antiinflammatory cascade might contribute to the skewing of the differentiation of monocytes toward the development of scavenger macrophages, which exhibit increased phagocytic activity and are CD163⫹. Consistent with this hypothesis is the observation that dendritic cells (DCs) transduced with SOCS3 exhibit a DC type 2 phenotype that directs Th2 responses (44). Although similar experiments have not been performed on macrophages, SOCS3 overexpression has been associated with the shift 3802 FALL ET AL Figure 4. Role of hemoglobin–haptoglobin (Hb–HP) scavenger receptor CD163, heme oxygenases, and ferritin in adaptation to oxidative stress induced by free heme and iron. Free heme is a source of redox active iron. To prevent cell damage caused by iron-derived reactive oxygen species, haptoglobin forms a complex with free hemoglobin. The hemoglobin–haptoglobin complexes then bind to CD163 and are internalized by the macrophage. Endocytosis of hemoglobin–haptoglobin complexes leads to up-regulation of heme oxygenase enzymatic activity. Heme oxygenase degrades the heme subunit of hemoglobin into biliverdin, which is subsequently converted to bilirubin, carbon monoxide, and free iron. The free iron is either sequestered in association with ferritin within the cell or transported and distributed to red blood cell precursors in the bone marrow. toward alternatively activated macrophage responses, at least in some experimental systems (45). Also in accordance with the hypothesis, increased expression of INHBA, another gene in the cluster, has also been associated with the alternative pathway of macrophage differentiation (38). Comparisons between systemic JIA patients grouped according to high versus normal ferritin levels also revealed statistically significant differences in the levels of expression of several genes whose products are critical to the activation of the cytolytic pathway. This includes Rab27a and SH2D1A (46,47). Mutations in these genes have been implicated in the development of type 2 Griscelli syndrome and X-linked lymphoproliferative disease, both associated with hemophagocytic syndrome. These observations suggest that the pathways that distinguish high-ferritin versus normal-ferritin systemic JIA may also be relevant to the development of the cytolytic abnormalities seen in patients with the disease. In contrast, perforin expression was low in most patients with systemic JIA, consistent with the trend toward lower numbers of NK cells as determined by flow cytometric analysis. The trend was particularly strong for CD56dim NK cells, a cell population that has been associated with particularly high levels of perforin expression (48). Another interesting finding was the relative paucity of genes whose expression is induced by IFN␥. The scarcity of IFN-induced genes in the list of genes distinguishing systemic JIA patients from controls is intriguing since the presence of IFN␥ in the serum of patients with systemic juvenile idiopathic arthritis has been demonstrated in many studies. One possible explanation is the altered responsiveness of immune cells to IFN␥. Indeed, SOCS3, one of the most highly overexpressed genes in our data set, has been shown to interact with the JAK/STAT signaling pathways, leading to decreased responsiveness of monocyte/macrophages to IFN␥ (41). GENE EXPRESSION PROFILING FOR MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JIA Taken together, these observations support the hypothesis that the antiinflammatory negative feedback loops induced by innate immune responses involving IL-1 and IL-6 may contribute to conditions that favor the alternative pathway of macrophage differentiation, leading to the development of the CD163⫹ “scavenger” phenotype. This phenotype is associated with increased phagocytic activity and has been implicated in the development of hemophagocytic syndromes. Interestingly, similar pathways involving mild hemophagocytosis have been described in septic shock syndrome (49,50), another TLR-triggered phenomenon in which IL-1 and IL-6 play a major role. In the presence of cytotoxic abnormalities, this may create a “set-up” for the development of full-blown macrophage activation syndrome. In summary, gene expression profiling of PBMCs from patients with untreated new-onset systemic JIA revealed molecular heterogeneity that corresponded to serum ferritin levels, a clinical feature that is important in the diagnosis of hemophagocytic syndromes including macrophage activation syndrome. The 3 main clusters of genes that contributed to the heterogeneity are those involved in erythropoiesis, cell cycle regulation, and negative regulation of the innate immune response (particularly those induced by TLR/IL-1R signaling). Based on these data we propose that the gene expression signature that includes these clusters may help identify patients at risk for the development of full-blown macrophage activation syndrome, in whom closer observation as well as timely treatment modifications may be required. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. AUTHOR CONTRIBUTIONS Dr. Grom had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study design. Fall, Barnes, Thornton, Ilowite, Gottlieb, Griffin, Sherry, Thompson, Glass, Colbert, Grom. Acquisition of data. Fall, Barnes, Luyrink, Olson, Ilowite, Gottlieb, Griffin, Sherry. Analysis and interpretation of data. Fall, Barnes, Thornton, Griffin, Thompson, Glass, Colbert, Grom. Manuscript preparation. Fall, Barnes, Thornton, Luyrink, Olson, Ilowite, Gottlieb, Griffin, Sherry, Thompson, Glass, Colbert, Grom. Statistical analysis. Fall, Barnes. 16. 17. 18. 19. 20. REFERENCES 1. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998;12:245–71. 2. Lang BA, Schneider R, Reilly BJ, Silverman ED, Laxer RM. Radiologic features of systemic onset juvenile rheumatoid arthritis. J Rheumatol 1995;22:168–73. 3. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic 21. 22. 3803 arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) 2005;44:1350–3. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2003;48 Suppl 9:S429. De Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? [editorial]. Arthritis Rheum 2005;52:687–93. Irigoyen PI, Olson J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra [abstract]. Arthritis Rheum 2004;50 Suppl 9:S437–8. Verbsky JW, White AJ. Effective use of recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071–5. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479–86. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatalonset multisystem inflammatory disease. Arthritis Rheum 2005;52: 1283–6. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1␤ inhibition. N Engl J Med 2006;355: 581–92. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985;106: 561–6. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421–6. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor ␣-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965–71. Behrens E, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133–8. Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002;20:121–23. Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? [review]. Arthritis Rheum 2004;50:689–98. Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders. Curr Opin Allergy Clin Immunol 2006;6:410–5. Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bachli E, Fehr J, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005;74:6–10. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the hemoglobin scavenger receptor. Nature 2001;409:198–201. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005;142: 481–9. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol 2000;67:97–103. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain 3804 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999;286:1957–9 Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analysis of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat 2006;27:62–8. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich AH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005;7: R30–7. Jarvis JN, Dozmorov I, Jiang K, Frank MB, Szodoray P, Alex P, et al. Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther 2004;6: R15–32. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610–5. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991–4. Nalbant D, Youn H, Nalbant SI, Sharma S, Cobos E, Beale EG, et al. FAM20: an evolutionary conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics 2005;6:11. Larghero J, Rea D, Brossard Y, van Nifterik J, Delasse V, Robert I, et al. Prospective flow cytometric evaluation of nucleated red blood cells in cord blood units and relationship with nucleated and CD34⫹ cell quantification. Transfusion 2006;46:403–6. Levy O. Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J Leukoc Biol 2004;76:909–25. Liang Y, Tedder TF. Identification of a CD20-, FcR1␤-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 2001;72:119–27. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006;177:7303–11. Wang J, Wu X, Simonavicius N, Tian H, Ling L. Medium-chain fatty acids as ligands for orphan G-protein-coupled receptor GPR84. J Biol Chem 2006;281:34457–64. Yang S, Zhou M, Fowler DE, Wang P. Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: downregulation of proinflammatory cytokines. Crit Care Med 2002;30:2729–35. Zudaire E, Portal-Nunez S, Cuttitta F. The central role of adrenomedullin in host defense. J Leukoc Biol 2006;80:237–44. Dankesreiter S, Hoess A, Schneider-Mergener J, Wagner H, Miethke T. Synthetic endotoxin-binding peptides block endotoxintriggered TNF-␣ production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J Immunol 2000;164: 4804–11. Ebert S, Zeretzke M, Nau R, Michel U. Microglial cells and peritoneal macrophages release activin A upon stimulation with Toll-like receptor agonists. Neurosci Lett 2007;413:241–4. Ogawa K, Funaba M, Chen Y, Tsujimoto M. Activin A functions FALL ET AL 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol 2006;177:6787–94. Uehara A, Sugawara Y, Kurata S, Fujimoto Y, Fukase K, Kusumoto S, et al. Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human epithelial cells. Cell Microbiol 2005;7:675–8. Nakamura A, Mori Y, Hagiwara K, Suzuki T, Sakakibara T, Kikuchi T, et al. Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med 2003;197:669–74. Stoiber D, Kovarik P, Cohney S, Johnston JA, Steinlein P, Decker T. Lipopolysacharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-␥. J Immunol 1999;163:2640–7. Wong PK, Egan PJ, Croker BA, O’Donnell K, Sims NA, Drake S, et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 2006;116:1571–81. Crocker BA, Krebs DL, Zhang J, Wormald S, Wilson TA, Stanley EG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003;4:540–5. Li Y, Chu N, Rostami A, Zhang GX. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol 2006;177:1679–88. Garn H, Siese A, Stumpf S, Barth PJ, Muller B, Gemsa D. Shift toward an alternatively activated macrophage response in lungs of NO2-exposed rats. Am J Respir Cell Mol Biol 2003;28:386–96. Menasche G, Pastural E, Feldman J, Certain S, Ersoy F, Dupuis S, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000;25:173–6. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2domain encoding gene. Nat Genet 1998;20:129–35. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. Trends Immunol 2001;22:633–40. Weaver LK, Pioli PA, Wardwell K, Vogel SN, Guyre PM. Upregulation of human monocyte CD163 upon activation of cellsurface Toll-like receptors. J Leukoc Biol 2007;81:663–71. Schaer DJ, Schaer CA, Schoedon G, Imhof A, Kurrer MO. Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haematol 2006;77: 432–6. Feldman J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, et al. Munc13-4 is essential for cytolytic granule fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003;115:461–73. Zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 2005;14:827–34. Barbosa MD, Nguyen QA, Tchernev VT, Ashley JA, Detter JC, Blaydes SM, et al. Identification of the homologous beige and Chediak–Higashi syndrome genes [published erratum appears in Nature 1997;385:97]. Nature 1996;382:262–5.